The predominant biomarker for HCC diagnosis and efficacy evaluation, α-fetoprotein (AFP), falls short for 30%–40% of HCC patients, particularly those with smaller tumors or at early stages, limiting its utility in diagnosis and prognosis (Farinati et al., 2006; Giannini et al., 2012). This evidence concerns the gene AFP and hepatocellular carcinoma.